T2 Biosystems Executive Compensation (FY23)
TTOO · Executive and director compensation, fiscal 2022 to 2023
Chief executive, fiscal 2023 ◇ John Sperzel | Latest say-on-pay support = July 21, 2023 |
Velarion Member: every covered company in one industry, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The T2 Biosystems brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
Data as of October 3, 2026Latest filing (DEF 14A): November 20, 2024
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
57 figures on this page: 55 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
What changed from fiscal 2022 to fiscal 2023
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Sperzel: $1,985,340 → $865,500 (56.4% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is T2 Biosystems' chief executive and what were they paid?
John Sperzel was paid $865,500 in total compensation as President, Chief Executive Officer and Chairman of the Board of Directors for fiscal 2023. Sperzel's total moved 56.4% lower from the $1,985,340 reported for fiscal 2022.
What was T2 Biosystems' say-on-pay result?
Shareholders supported the say-on-pay proposal with 85.8% of votes cast for or against in favor at the meeting held July 21, 2023 for fiscal 2022.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Sperzel President, Chief Executive Officer and Chairman of the Board of Directors | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Michael Gibbs SVP and General Counsel | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
John Sprague Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
John Sperzel President, Chief Executive Officer and Chairman of the Board of Directors | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
Michael Gibbs SVP and General Counsel | ◇ | ◇ | — | — | ◇ | — | ◇ | ◇ |
John Sprague Chief Financial Officer | ◇ | ◇ | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2023 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| John Sperzel | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
John Sperzel
President, Chief Executive Officer and Chairman of the Board of Directors · Employment agreement
| Severance multiple | ◇ |
| Change-in-control multiple | ◇ |
John Sprague
Chief Financial Officer · Change-in-control agreement
| Change-in-control multiple | ◇ |
Michael Gibbs
SVP and General Counsel · Change-in-control agreement
| Change-in-control multiple | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2023
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
John W. Cumming Lead independent director | ◇ | — | — | — | — | — | ◇ |
David B. Elsbree | ◇ | — | — | — | — | — | ◇ |
Robin Toft | ◇ | — | — | — | — | — | ◇ |
Thierry Bernard | ◇ | — | — | — | — | — | ◇ |
Ninfa M. Saunders | ◇ | — | — | — | — | — | ◇ |
Seymour Liebman | ◇ | — | — | — | — | — | ◇ |
Laura Adams | ◇ | — | — | — | — | — | ◇ |
John Sperzel served on the board in fiscal 2023 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2022 | July 21, 2023 | = | ◇ | ◇ | ◇ |
| 2019 | August 6, 2020 | = | ◇ | ◇ | ◇ |
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- John Sperzel (President, Chief Executive Officer and Chairman of the Board of Directors), FY2023 total compensation $865,500 (base salary $575,000) [exec_comp, SEC accession 0001193125-24-262554, filed 2024-11-20]What this page does not include
Everything above is a fact T2 Biosystems disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
57 figures on this page: 55 cited to the filing that reported them, 2 calculated from figures it prints.
55 cited to the filing
2 calculated from the filing
Documents cited
- 0001193125-24-2625542023 Summary Compensation Table · Director Compensation Table2023 · Outstanding Equity Awards at Fiscal Year-End Table2023 · Proxy severance section
- 0001193125-23-236990Proposal 3: Approval, on an Advisory Basis of the Compensation of the Named Executive Officers For Against Abstain Broker Non-Votes
- 0001193125-23-1941792022 Summary Compensation Table
- 0001193125-20-213399
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “T2 Biosystems executive compensation, FY2022–FY2023.” https://intel.velarion.ai/comp/TTOO (accessed 2026).
Short form: data: Velarion
The T2 Biosystems brief, $1,500
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
Both reports for $2,400.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about T2 Biosystems and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}